Needham lowered the firm’s price target on TransMedics (TMDX) to $142 from $174 and keeps a Buy rating on the shares. The company’s Q1 revenue and earnings missed consensus estimates, with the firm also citing enrollment challenges with its DENOVO and ENHANCE trials, the analyst tells investors in a research note. Needham adds its reduced price target reflects peer multiple compression and its lower estimates for 2027 revenue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Buy Rating Reiterated as Transplant Volumes Support Growth; $190 Price Target Maintained
- TransMedics signs agreement to invest in PAD Aviation
- TransMedics Maintained at Buy as CHOPS Platform Broadens Transplant Offering; $152 Price Target Reiterated
- TransMedics: Strengthening Leadership in Organ Preservation Through Rigorous Clinical Trials and Normothermic Perfusion Evidence
- William Blair healthcare IT analysts hold analyst/industry conference call